查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2041727

Gabapentin市場預測至2034年－按產品類型、類別、給藥途徑、購買方式、應用、最終用戶和地區分類的全球分析

Gabapentin Market Forecasts to 2034 - Global Analysis By Product (Tablet, Capsule and Other Products), Type (Generic, Branded and Other Types), Route of Administration, Mode of Purchase, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球Gabapentin市場規模將達到 26 億美元，並在預測期內以 7.4% 的複合年成長率成長，到 2034 年將達到 46 億美元。

Gabapentin是一種主要用作抗驚厥藥物和緩解神經性疼痛的藥物，其作用機制是透過模擬神經傳導物質γ-氨基丁酸（GABA）的作用。該藥已獲得美國食品藥物管理局（FDA）核准，用於治療多種疾病，包括癲癇、帶狀皰疹後遺症神經痛和不寧腿症候群。由於在神經系統疾病和慢性疼痛治療​​方面具有廣泛的適應症，加巴噴丁是現代醫學中重要的藥物。

根據一份報告顯示，2020 年Gabapentin在美國處方藥中排名第 6 位。當年，美國開出了約 5,700 萬處方箋處方。

提高意識

醫療專業人員和患者對這種藥物在治療各種Gabapentin疾病和神經性疼痛方面的療效有了更深入的了解。隨著醫生們對該藥物的作用機制及其有效治療的多種疾病有了更清晰的認知，他們也越來越頻繁地開立這種藥物。此外，以患者為中心的醫療保健市場格局的演變正在推動知情決策，而這種認知的提高是市場成長的關鍵促進因素。

誤用和濫用

濫用Gabapentin包括服用超過處方劑量、未經處方箋使用或與其他物質混合使用以增強藥效。濫用Gabapentin可導致多種副作用，包括頭暈、鎮靜、協調能力下降、視力障礙和認知障礙。此外，長期濫用或誤用Gabapentin後突然停藥會導致焦慮、失眠和躁動等戒斷症狀，這會嚴重阻礙其市場擴張。

遠端醫療的擴展

遠端醫療服務的擴展正在促進醫療保健事業的發展，並透過方便將加巴噴丁送達需要用於治療神經系統疾病和神經病變疼痛的患者，從而積極影響Gabapentin的可及性。遠端醫療使醫療專業人員能夠進行遠距會診、開立處方並監測患者病情。此外，遠端醫療還允許醫療專業人員遠端監測患者、快速回應患者提出的問題並最佳化藥物管理，這些都推動了市場成長。

副作用和耐受性

Gabapentin副作用的頻繁發生給醫療專業人員帶來了挑戰，他們需要在權衡其治療益處和潛在弊端之間做出權衡。患者的年齡、潛在疾病和合併用藥等個別因素會影響副作用發生的機率和嚴重程度。此外，副作用的發生可能需要額外的醫療干預，從而增加醫療成本和資源消耗，最終阻礙市場成長。

新冠疫情的影響

新冠疫情對Gabapentin市場造成了多方面的負面影響。供應鏈中斷、封鎖措施以及醫療保健重點的轉變，共同導致Gabapentin的生產、分銷和消費面臨挑戰。經濟的不確定性和醫療保健系統面臨的財政負擔促使各方採取成本削減措施，這可能會影響Gabapentin的供應。此外，患者就診量的減少可能導致新處方箋和處方箋數量下降，從而影響整體市場需求。

在預測期內，膠囊細分市場預計將佔據最大佔有率。

膠囊劑預計將佔據最大的市場佔有率。這些藥物廣泛用於治療神經系統疾病和神經性疼痛，對神經病變、帶狀皰疹後遺症神經痛和糖尿病神經病變等疾病療效顯著。研發投入、監管核准和策略聯盟等因素正在影響市場動態。此外，對創新、安全性和可近性的關注仍然是整個醫藥市場的關鍵要素，並推動該細分市場的成長。

在預測期內，腸外給藥領域預計將呈現最高的複合年成長率。

預計在預測期內，腸外給藥領域將呈現最高的複合年成長率，因為它具有明顯的優勢，尤其是在口服給藥困難的情況下，例如噁心、嘔吐或吞嚥困難的患者。這種給藥方式可以提高治療順從性，並確保患者能準確服用處方劑量。此外，腸外Gabapentin製劑對於需要快速起效和精確劑量控制的患者來說是一種有效的替代方案，從而推動了該領域的成長。

市佔率最大的地區：

在預測期內，北美佔據了最大的市場佔有率，這反映了製藥業在神經系統疾病和神經病變疼痛治療​​領域的重要地位。輝瑞、梯瓦製藥、格蘭馬克製藥和西普拉丁美洲國等領導企業在癲癇、帶狀皰疹後遺症神經痛和糖尿病神經神經病變等疾病的治療中發揮核心作用。此外，美國食品藥物管理局（FDA）和加拿大衛生署等監管機構的監督，確保了該地區藥品符合安全標準並有效分銷。

複合年成長率最高的地區：

由於Gabapentin在治療癲癇、帶狀皰疹後遺症神經痛和糖尿病神經病變等疾病方面的有效性，預計歐洲在預測期內將實現最高的複合年成長率。製藥公司正努力滿足日益成長的加巴噴丁需求，旨在為歐洲神經系統疾病患者提供有效的治療方案。此外，神經系統疾病盛行率的上升、人口老化以及人們對慢性疼痛管理意識的提高等因素，也正在推動該地區的市場擴張。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球Gabapentin市場：依產品分類

  • 藥片
  • 膠囊
  • 其他產品

第6章：全球Gabapentin市場：按類型分類

  • 非專利的
  • 品牌
  • 其他類型

第7章：全球Gabapentin市場：依給藥途徑分類

  • 腸外
  • 口服
  • 靜脈
  • 其他給藥途徑

第8章：全球Gabapentin市場：以購買方式分類

  • 處方
  • 非處方藥
  • 零售

第9章：全球Gabapentin市場：按應用分類

  • 神經性疼痛
  • 癲癇
  • 不寧腿
  • 其他用途

第10章 全球Gabapentin市場：依最終用戶分類

  • 網路藥房
  • 醫院藥房
  • 其他最終用戶

第11章 全球Gabapentin市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第12章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第13章：公司簡介

  • Amneal Pharmaceuticals LLC.
  • Intas Pharmaceuticals Ltd.
  • Sun Pharmaceutical Industries Ltd
  • Marksans Pharma
  • Novartis AG
  • Alkem Labs
  • Jiangsu Nhwa Pharmaceutical Co., Ltd
  • Aurobindo Pharma
  • Apotex Inc
  • Viatris Inc
  • Arbor Pharmaceuticals, LLC
  • Pfizer Inc
  • Teva Pharmaceuticals Ltd
  • Glenmark Pharmaceuticals Limited
  • Ascend Laboratories, LLC
  • Cipla USA, Inc.
Product Code: SMRC24790

According to Stratistics MRC, the Global Gabapentin Market is accounted for $2.6 billion in 2026 and is expected to reach $4.6 billion by 2034 growing at a CAGR of 7.4% during the forecast period. Gabapentin is a pharmaceutical compound used primarily as an anticonvulsant and to alleviate neuropathic pain which mimic the neurotransmitter gamma-aminobutyric acid (GABA). It is approved by the U.S. Food and Drug Administration (FDA), and is employed in the treatment of various medical conditions, including epilepsy, postherpetic neuralgia, and restless legs syndrome. The drug's versatility in addressing neurological disorders and chronic pain has made it a valuable asset in modern medicine.

According to a report, gabapentin ranks sixth in prescribed medication in the United States in 2020. Nearly, 57 million prescriptions were written for the drug in the country in 2020.

Market Dynamics:

Driver:

Increase in awareness

Healthcare professionals and patients are becoming more informed about the drug's efficacy in managing various neurological disorders and neuropathic pain conditions. Physicians are increasingly prescribing Gabapentin based on a deeper understanding of its mechanisms of action and the diverse range of conditions it can effectively address. In addition, the evolving landscape of patient-centered healthcare encourages informed decision-making, making awareness a crucial factor in driving this market.

Restraint:

Misuse and abuse

Gabapentin misuse can involve taking higher doses than prescribed, using it without a prescription, or combining it with other substances to intensify the desired effects. Abuse of gabapentin can result in various adverse effects, including dizziness, sedation, impaired coordination, blurred vision, and cognitive difficulties. Furthermore, abrupt discontinuation of gabapentin after prolonged misuse or abuse can result in withdrawal symptoms such as anxiety, insomnia, and restlessness, significantly hampering this market expansion.

Opportunity:

Telehealth expansion

The expansion of telehealth services serves healthcare and positively impacts the accessibility of this medication by transforming easy delivery for individuals requiring gabapentin for neurological disorders and neuropathic pain. Telehealth allows healthcare providers to conduct remote consultations, prescribe medications, and monitor patients' conditions from a distance. Further, telehealth enables healthcare professionals to monitor patients remotely, address concerns promptly, and optimize medication management, which is propelling this market

Threat:

Side effects and tolerance

The prevalence of side effects poses challenges for healthcare providers in balancing the therapeutic benefits of Gabapentin with its potential drawbacks. Patient-specific factors, such as age, underlying health conditions, and concurrent medications, can influence the likelihood and severity of side effects. Moreover, the presence of side effects may necessitate additional medical interventions, contributing to healthcare costs and resource utilization and thereby hindering market growth.

Covid-19 Impact

The COVID-19 pandemic has had several negative impacts on the Gabapentin market. Supply chain disruptions, lockdown measures, and shifts in healthcare priorities have collectively contributed to challenges in the production, distribution, and consumption of gabapentin. Economic uncertainties and financial strains on healthcare systems have prompted cost-cutting measures, potentially influencing the affordability of Gabapentin. Moreover, reduced patient visits to healthcare providers may have led to a decline in new prescriptions and refills, affecting overall market demand.

The capsule segment is expected to be the largest during the forecast period

The capsule segment is estimated to hold the largest share. These are pharmaceutical products widely prescribed for neurological disorders and neuropathic pain that are efficient in managing conditions like epilepsy, postherpetic neuralgia, and diabetic neuropathy. Factors such as research and development initiatives, regulatory approvals, and strategic collaborations influence market dynamics. Furthermore, a focus on innovation, safety, and accessibility continues to be a vital contributor to the broader pharmaceutical market, driving this segment's growth.

The parenteral segment is expected to have the highest CAGR during the forecast period

The parenteral segment is anticipated to have highest CAGR during the forecast period due to distinct advantages, particularly in situations where oral intake may be challenging, such as for patients experiencing nausea, vomiting, or those with difficulty swallowing. This mode of delivery enhances treatment compliance and ensures patients receive the prescribed dosage accurately. Additionally, for individuals requiring rapid onset of action or precise dosage control, parenteral formulations of gabapentin provide an effective alternative, boosting this segment's expansion.

Region with largest share:

North America commanded the largest market share during the extrapolated period owing to its significant presence in the pharmaceutical landscape, addressing neurological disorders and neuropathic pain. Key markets such as Pfizer Inc., Teva Pharmaceuticals Ltd., Glenmark Pharmaceuticals Limited, and Cipla USA Inc. have become cornerstones in the management of conditions like epilepsy, postherpetic neuralgia, and diabetic neuropathy. Furthermore, regulatory oversight from agencies like the U.S. Food and Drug Administration (FDA) and Health Canada ensures compliance with safety standards and effective distribution in this region.

Region with highest CAGR:

Europe is expected to witness highest CAGR over the projection period, owing to its efficacy in managing conditions like epilepsy, postherpetic neuralgia, and diabetic neuropathy. Pharmaceutical companies engage in manufacturing and marketing activities to meet the increasing demand for Gabapentin, aiming to provide effective solutions for individuals grappling with neurological conditions in Europe. In addition, factors such as the rising prevalence of neurological disorders, an aging population, and an increased awareness of chronic pain management are boosting this region's expansion.

Key players in the market

Some of the key players in the Gabapentin Market include Amneal Pharmaceuticals LLC., Intas Pharmaceuticals Ltd., Sun Pharmaceutical Industries Ltd, Marksans Pharma, Novartis AG, Alkem Labs, Jiangsu Nhwa Pharmaceutical Co., Ltd, Aurobindo Pharma, Apotex Inc, Viatris Inc, Arbor Pharmaceuticals, LLC, Pfizer Inc, Teva Pharmaceuticals Ltd, Glenmark Pharmaceuticals Limited, Ascend Laboratories, LLC and Cipla USA, Inc.

Key Developments:

In December 2023, Pfizer Inc. announced the successful completion of its acquisition of Seagen Inc, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.

In October 2023, Zydus Lifesciences Company and Sun Pharmaceutical Industries Limited announced that both companies have entered into a licensing agreement to co-market an innovative drug, Desidustat in India.

In January 2023, Sun Pharmaceutical Industries Limited and Concert Pharmaceuticals, Inc. announced that they have executed a definitive agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment in equity value.

Products Covered:

  • Tablet
  • Capsule
  • Other Products

Types Covered:

  • Generic
  • Branded
  • Other Types

Route of Administrations Covered:

  • Parenteral
  • Oral
  • Intravenous
  • Other Route of Administrations

Mode of Purchase Covered:

  • Prescription
  • Over the Counter(OTC)
  • Retail

Applications Covered:

  • Neuropathic Pain
  • Epilepsy
  • Restless Legs Syndrome
  • Other Applications

End Users Covered:

  • Online Pharmacies
  • Hospital Pharmacy
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Gabapentin Market, By Product

  • 5.1 Introduction
  • 5.2 Tablet
  • 5.3 Capsule
  • 5.4 Other Products

6 Global Gabapentin Market, By Type

  • 6.1 Introduction
  • 6.2 Generic
  • 6.3 Branded
  • 6.4 Other Types

7 Global Gabapentin Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Parenteral
  • 7.3 Oral
  • 7.4 Intravenous
  • 7.5 Other Route of Administrations

8 Global Gabapentin Market, By Mode of Purchase

  • 8.1 Introduction
  • 8.2 Prescription
  • 8.3 Over the Counter (OTC)
  • 8.4 Retail

9 Global Gabapentin Market, By Application

  • 9.1 Introduction
  • 9.2 Neuropathic Pain
  • 9.3 Epilepsy
  • 9.4 Restless Legs Syndrome
  • 9.5 Other Applications

10 Global Gabapentin Market, By End User

  • 10.1 Introduction
  • 10.2 Online Pharmacies
  • 10.3 Hospital Pharmacy
  • 10.4 Other End Users

11 Global Gabapentin Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Amneal Pharmaceuticals LLC.
  • 13.2 Intas Pharmaceuticals Ltd.
  • 13.3 Sun Pharmaceutical Industries Ltd
  • 13.4 Marksans Pharma
  • 13.5 Novartis AG
  • 13.6 Alkem Labs
  • 13.7 Jiangsu Nhwa Pharmaceutical Co., Ltd
  • 13.8 Aurobindo Pharma
  • 13.9 Apotex Inc
  • 13.10 Viatris Inc
  • 13.11 Arbor Pharmaceuticals, LLC
  • 13.12 Pfizer Inc
  • 13.13 Teva Pharmaceuticals Ltd
  • 13.14 Glenmark Pharmaceuticals Limited
  • 13.15 Ascend Laboratories, LLC
  • 13.16 Cipla USA, Inc.

List of Tables

  • Table 1 Global Gabapentin Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Gabapentin Market Outlook, By Product (2023-2034) ($MN)
  • Table 3 Global Gabapentin Market Outlook, By Tablet (2023-2034) ($MN)
  • Table 4 Global Gabapentin Market Outlook, By Capsule (2023-2034) ($MN)
  • Table 5 Global Gabapentin Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 6 Global Gabapentin Market Outlook, By Type (2023-2034) ($MN)
  • Table 7 Global Gabapentin Market Outlook, By Generic (2023-2034) ($MN)
  • Table 8 Global Gabapentin Market Outlook, By Branded (2023-2034) ($MN)
  • Table 9 Global Gabapentin Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 10 Global Gabapentin Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 11 Global Gabapentin Market Outlook, By Parenteral (2023-2034) ($MN)
  • Table 12 Global Gabapentin Market Outlook, By Oral (2023-2034) ($MN)
  • Table 13 Global Gabapentin Market Outlook, By Intravenous (2023-2034) ($MN)
  • Table 14 Global Gabapentin Market Outlook, By Other Route of Administrations (2023-2034) ($MN)
  • Table 15 Global Gabapentin Market Outlook, By Mode of Purchase (2023-2034) ($MN)
  • Table 16 Global Gabapentin Market Outlook, By Prescription (2023-2034) ($MN)
  • Table 17 Global Gabapentin Market Outlook, By Over the Counter (OTC) (2023-2034) ($MN)
  • Table 18 Global Gabapentin Market Outlook, By Retail (2023-2034) ($MN)
  • Table 19 Global Gabapentin Market Outlook, By Application (2023-2034) ($MN)
  • Table 20 Global Gabapentin Market Outlook, By Neuropathic Pain (2023-2034) ($MN)
  • Table 21 Global Gabapentin Market Outlook, By Epilepsy (2023-2034) ($MN)
  • Table 22 Global Gabapentin Market Outlook, By Restless Legs Syndrome (2023-2034) ($MN)
  • Table 23 Global Gabapentin Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 24 Global Gabapentin Market Outlook, By End User (2023-2034) ($MN)
  • Table 25 Global Gabapentin Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 26 Global Gabapentin Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 27 Global Gabapentin Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 28 North America Gabapentin Market Outlook, By Country (2023-2034) ($MN)
  • Table 29 North America Gabapentin Market Outlook, By Product (2023-2034) ($MN)
  • Table 30 North America Gabapentin Market Outlook, By Tablet (2023-2034) ($MN)
  • Table 31 North America Gabapentin Market Outlook, By Capsule (2023-2034) ($MN)
  • Table 32 North America Gabapentin Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 33 North America Gabapentin Market Outlook, By Type (2023-2034) ($MN)
  • Table 34 North America Gabapentin Market Outlook, By Generic (2023-2034) ($MN)
  • Table 35 North America Gabapentin Market Outlook, By Branded (2023-2034) ($MN)
  • Table 36 North America Gabapentin Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 37 North America Gabapentin Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 38 North America Gabapentin Market Outlook, By Parenteral (2023-2034) ($MN)
  • Table 39 North America Gabapentin Market Outlook, By Oral (2023-2034) ($MN)
  • Table 40 North America Gabapentin Market Outlook, By Intravenous (2023-2034) ($MN)
  • Table 41 North America Gabapentin Market Outlook, By Other Route of Administrations (2023-2034) ($MN)
  • Table 42 North America Gabapentin Market Outlook, By Mode of Purchase (2023-2034) ($MN)
  • Table 43 North America Gabapentin Market Outlook, By Prescription (2023-2034) ($MN)
  • Table 44 North America Gabapentin Market Outlook, By Over the Counter (OTC) (2023-2034) ($MN)
  • Table 45 North America Gabapentin Market Outlook, By Retail (2023-2034) ($MN)
  • Table 46 North America Gabapentin Market Outlook, By Application (2023-2034) ($MN)
  • Table 47 North America Gabapentin Market Outlook, By Neuropathic Pain (2023-2034) ($MN)
  • Table 48 North America Gabapentin Market Outlook, By Epilepsy (2023-2034) ($MN)
  • Table 49 North America Gabapentin Market Outlook, By Restless Legs Syndrome (2023-2034) ($MN)
  • Table 50 North America Gabapentin Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 51 North America Gabapentin Market Outlook, By End User (2023-2034) ($MN)
  • Table 52 North America Gabapentin Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 53 North America Gabapentin Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 54 North America Gabapentin Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 55 Europe Gabapentin Market Outlook, By Country (2023-2034) ($MN)
  • Table 56 Europe Gabapentin Market Outlook, By Product (2023-2034) ($MN)
  • Table 57 Europe Gabapentin Market Outlook, By Tablet (2023-2034) ($MN)
  • Table 58 Europe Gabapentin Market Outlook, By Capsule (2023-2034) ($MN)
  • Table 59 Europe Gabapentin Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 60 Europe Gabapentin Market Outlook, By Type (2023-2034) ($MN)
  • Table 61 Europe Gabapentin Market Outlook, By Generic (2023-2034) ($MN)
  • Table 62 Europe Gabapentin Market Outlook, By Branded (2023-2034) ($MN)
  • Table 63 Europe Gabapentin Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 64 Europe Gabapentin Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 65 Europe Gabapentin Market Outlook, By Parenteral (2023-2034) ($MN)
  • Table 66 Europe Gabapentin Market Outlook, By Oral (2023-2034) ($MN)
  • Table 67 Europe Gabapentin Market Outlook, By Intravenous (2023-2034) ($MN)
  • Table 68 Europe Gabapentin Market Outlook, By Other Route of Administrations (2023-2034) ($MN)
  • Table 69 Europe Gabapentin Market Outlook, By Mode of Purchase (2023-2034) ($MN)
  • Table 70 Europe Gabapentin Market Outlook, By Prescription (2023-2034) ($MN)
  • Table 71 Europe Gabapentin Market Outlook, By Over the Counter (OTC) (2023-2034) ($MN)
  • Table 72 Europe Gabapentin Market Outlook, By Retail (2023-2034) ($MN)
  • Table 73 Europe Gabapentin Market Outlook, By Application (2023-2034) ($MN)
  • Table 74 Europe Gabapentin Market Outlook, By Neuropathic Pain (2023-2034) ($MN)
  • Table 75 Europe Gabapentin Market Outlook, By Epilepsy (2023-2034) ($MN)
  • Table 76 Europe Gabapentin Market Outlook, By Restless Legs Syndrome (2023-2034) ($MN)
  • Table 77 Europe Gabapentin Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 78 Europe Gabapentin Market Outlook, By End User (2023-2034) ($MN)
  • Table 79 Europe Gabapentin Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 80 Europe Gabapentin Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 81 Europe Gabapentin Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 82 Asia Pacific Gabapentin Market Outlook, By Country (2023-2034) ($MN)
  • Table 83 Asia Pacific Gabapentin Market Outlook, By Product (2023-2034) ($MN)
  • Table 84 Asia Pacific Gabapentin Market Outlook, By Tablet (2023-2034) ($MN)
  • Table 85 Asia Pacific Gabapentin Market Outlook, By Capsule (2023-2034) ($MN)
  • Table 86 Asia Pacific Gabapentin Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 87 Asia Pacific Gabapentin Market Outlook, By Type (2023-2034) ($MN)
  • Table 88 Asia Pacific Gabapentin Market Outlook, By Generic (2023-2034) ($MN)
  • Table 89 Asia Pacific Gabapentin Market Outlook, By Branded (2023-2034) ($MN)
  • Table 90 Asia Pacific Gabapentin Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 91 Asia Pacific Gabapentin Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 92 Asia Pacific Gabapentin Market Outlook, By Parenteral (2023-2034) ($MN)
  • Table 93 Asia Pacific Gabapentin Market Outlook, By Oral (2023-2034) ($MN)
  • Table 94 Asia Pacific Gabapentin Market Outlook, By Intravenous (2023-2034) ($MN)
  • Table 95 Asia Pacific Gabapentin Market Outlook, By Other Route of Administrations (2023-2034) ($MN)
  • Table 96 Asia Pacific Gabapentin Market Outlook, By Mode of Purchase (2023-2034) ($MN)
  • Table 97 Asia Pacific Gabapentin Market Outlook, By Prescription (2023-2034) ($MN)
  • Table 98 Asia Pacific Gabapentin Market Outlook, By Over the Counter (OTC) (2023-2034) ($MN)
  • Table 99 Asia Pacific Gabapentin Market Outlook, By Retail (2023-2034) ($MN)
  • Table 100 Asia Pacific Gabapentin Market Outlook, By Application (2023-2034) ($MN)
  • Table 101 Asia Pacific Gabapentin Market Outlook, By Neuropathic Pain (2023-2034) ($MN)
  • Table 102 Asia Pacific Gabapentin Market Outlook, By Epilepsy (2023-2034) ($MN)
  • Table 103 Asia Pacific Gabapentin Market Outlook, By Restless Legs Syndrome (2023-2034) ($MN)
  • Table 104 Asia Pacific Gabapentin Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 105 Asia Pacific Gabapentin Market Outlook, By End User (2023-2034) ($MN)
  • Table 106 Asia Pacific Gabapentin Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 107 Asia Pacific Gabapentin Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 108 Asia Pacific Gabapentin Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 109 South America Gabapentin Market Outlook, By Country (2023-2034) ($MN)
  • Table 110 South America Gabapentin Market Outlook, By Product (2023-2034) ($MN)
  • Table 111 South America Gabapentin Market Outlook, By Tablet (2023-2034) ($MN)
  • Table 112 South America Gabapentin Market Outlook, By Capsule (2023-2034) ($MN)
  • Table 113 South America Gabapentin Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 114 South America Gabapentin Market Outlook, By Type (2023-2034) ($MN)
  • Table 115 South America Gabapentin Market Outlook, By Generic (2023-2034) ($MN)
  • Table 116 South America Gabapentin Market Outlook, By Branded (2023-2034) ($MN)
  • Table 117 South America Gabapentin Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 118 South America Gabapentin Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 119 South America Gabapentin Market Outlook, By Parenteral (2023-2034) ($MN)
  • Table 120 South America Gabapentin Market Outlook, By Oral (2023-2034) ($MN)
  • Table 121 South America Gabapentin Market Outlook, By Intravenous (2023-2034) ($MN)
  • Table 122 South America Gabapentin Market Outlook, By Other Route of Administrations (2023-2034) ($MN)
  • Table 123 South America Gabapentin Market Outlook, By Mode of Purchase (2023-2034) ($MN)
  • Table 124 South America Gabapentin Market Outlook, By Prescription (2023-2034) ($MN)
  • Table 125 South America Gabapentin Market Outlook, By Over the Counter (OTC) (2023-2034) ($MN)
  • Table 126 South America Gabapentin Market Outlook, By Retail (2023-2034) ($MN)
  • Table 127 South America Gabapentin Market Outlook, By Application (2023-2034) ($MN)
  • Table 128 South America Gabapentin Market Outlook, By Neuropathic Pain (2023-2034) ($MN)
  • Table 129 South America Gabapentin Market Outlook, By Epilepsy (2023-2034) ($MN)
  • Table 130 South America Gabapentin Market Outlook, By Restless Legs Syndrome (2023-2034) ($MN)
  • Table 131 South America Gabapentin Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 132 South America Gabapentin Market Outlook, By End User (2023-2034) ($MN)
  • Table 133 South America Gabapentin Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 134 South America Gabapentin Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 135 South America Gabapentin Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 136 Middle East & Africa Gabapentin Market Outlook, By Country (2023-2034) ($MN)
  • Table 137 Middle East & Africa Gabapentin Market Outlook, By Product (2023-2034) ($MN)
  • Table 138 Middle East & Africa Gabapentin Market Outlook, By Tablet (2023-2034) ($MN)
  • Table 139 Middle East & Africa Gabapentin Market Outlook, By Capsule (2023-2034) ($MN)
  • Table 140 Middle East & Africa Gabapentin Market Outlook, By Other Products (2023-2034) ($MN)
  • Table 141 Middle East & Africa Gabapentin Market Outlook, By Type (2023-2034) ($MN)
  • Table 142 Middle East & Africa Gabapentin Market Outlook, By Generic (2023-2034) ($MN)
  • Table 143 Middle East & Africa Gabapentin Market Outlook, By Branded (2023-2034) ($MN)
  • Table 144 Middle East & Africa Gabapentin Market Outlook, By Other Types (2023-2034) ($MN)
  • Table 145 Middle East & Africa Gabapentin Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 146 Middle East & Africa Gabapentin Market Outlook, By Parenteral (2023-2034) ($MN)
  • Table 147 Middle East & Africa Gabapentin Market Outlook, By Oral (2023-2034) ($MN)
  • Table 148 Middle East & Africa Gabapentin Market Outlook, By Intravenous (2023-2034) ($MN)
  • Table 149 Middle East & Africa Gabapentin Market Outlook, By Other Route of Administrations (2023-2034) ($MN)
  • Table 150 Middle East & Africa Gabapentin Market Outlook, By Mode of Purchase (2023-2034) ($MN)
  • Table 151 Middle East & Africa Gabapentin Market Outlook, By Prescription (2023-2034) ($MN)
  • Table 152 Middle East & Africa Gabapentin Market Outlook, By Over the Counter (OTC) (2023-2034) ($MN)
  • Table 153 Middle East & Africa Gabapentin Market Outlook, By Retail (2023-2034) ($MN)
  • Table 154 Middle East & Africa Gabapentin Market Outlook, By Application (2023-2034) ($MN)
  • Table 155 Middle East & Africa Gabapentin Market Outlook, By Neuropathic Pain (2023-2034) ($MN)
  • Table 156 Middle East & Africa Gabapentin Market Outlook, By Epilepsy (2023-2034) ($MN)
  • Table 157 Middle East & Africa Gabapentin Market Outlook, By Restless Legs Syndrome (2023-2034) ($MN)
  • Table 158 Middle East & Africa Gabapentin Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 159 Middle East & Africa Gabapentin Market Outlook, By End User (2023-2034) ($MN)
  • Table 160 Middle East & Africa Gabapentin Market Outlook, By Online Pharmacies (2023-2034) ($MN)
  • Table 161 Middle East & Africa Gabapentin Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 162 Middle East & Africa Gabapentin Market Outlook, By Other End Users (2023-2034) ($MN)